Geoffrey Gogniat

Title: Geoffrey Gogniat: Innovator in Pharmaceutical Composition

Introduction

Geoffrey Gogniat is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmacy, particularly in the development of pharmaceutical compositions. With a total of 2 patents to his name, Gogniat's work focuses on innovative solutions for oral administration of medications.

Latest Patents

Gogniat's latest patents include a pharmaceutical composition that comprises an inert substrate and a mixture containing a non-bile acid farnesoid X receptor (FXR) agonist. This composition is designed for oral administration and includes a specific compound, 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof. Additionally, he has developed another pharmaceutical composition that includes a non-bile farnesoid X receptor (FXR) agonist and at least one lipid excipient, aimed at treating FXR mediated disorders.

Career Highlights

Gogniat is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on advancing pharmaceutical innovations that can improve patient outcomes. His expertise in pharmaceutical compositions has positioned him as a key player in the industry.

Collaborations

Throughout his career, Gogniat has collaborated with esteemed colleagues such as Ulrich Meier and Claus Dieter Bischoff. These collaborations have further enriched his research and development efforts in the pharmaceutical field.

Conclusion

Geoffrey Gogniat's contributions to pharmaceutical compositions demonstrate his commitment to innovation in healthcare. His patents reflect a deep understanding of complex pharmaceutical formulations that can lead to significant advancements in treatment options.